We evaluated the diffusion of pefloxacin into the cerebrospinal fluid (CSF) in 15 patients with bacterial meningitis or ventriculitis, 14 of whom were treated with other antibiotics. Three doses of pefloxacin were administered at 12-h intervals to 11 patients intravenously and to 4 patients orally. Individual doses were 7.5 mg/kg in seven patients and 15 mg/kg in eight patients. Plasma and CSF levels were determined by a highperformance liquid chromatographic assay. The concentrations of pefloxacin in CSF were measured 2 h after the third intravenous dose and 4 h after the third oral dose. In patients receiving 7.5 mg/kg, peak levels in plasma ranged from 6.8 to 16 ,ug/ml, and trough levels were from 2 to 7.5 ,ug/ml. Concentrations in CSF ranged from 2.4 to 9 ,ug/ml. In patients receiving 15 mg/kg, peak levels in plasma ranged from 14 to 18.6 tig/ml, and trough levels were from 4 to 13.2 ,ug/ml. Concentrations in CSF ranged from 6.5 to 13 ,ug/ml. These preliminary data indicate that pefloxacin diffuses well into the CSF of patients with inflamed meninges.
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Pefloxacin is a new methyl-4-piperazinyl quinolone with high activity against both gram-negative and gram-positive organisms (J. Duval, J. F. Acar, E. Bergogne-Berezin, D. Christol, A. L. Courtieu, J. Fleurette, M. B. Lareng, C. Morel, and A. Thabaut. Int. Congr. Chemother. 13th, Vienna, Austria, p.63/7-63/13, 1983). In a recent study, it has been demonstrated that high concentrations of pefloxacin may be achieved in the cerebrospinal fluid (CSF) in both normal dogs and those with experimentally induced meningitis (M. Armengaud, V. T. Tran, and B. DiConstanzo. Int. Congr. Chemother. 13th, Vienna, Austria, p. 63/23-63/28, 1983). The results of these in vitro and animal studies led to the current evaluation of the penetration of pefloxacin into the CSF of patients with bacterial meningitis who were undergoing concurrent treatment with other antibiotics.
MATERIALS AND METHODS Patients. A total of 15 hospitalized patients, 10 with purulent meningitis and 5 with associated ventriculitis, were included in the study. There were 13 adults and 2 children and 11 males and 4 females. Ages ranged from 7 to 76 years. Leukocyte counts ranged from 66 to 14,000 cells per mm3 of CSF with a predominance of polymorphonuclear leukocytes (60 to 100%) in all patients. CSF protein concentrations were elevated (68 to 700 mg/dl). The ratio of glucose in CSF to blood was markedly decreased in all cases. Antibiotic treatment. All 15 patients were under treatment with other antibiotics (Table 1) . Of these patients, two (patients 14 and 15) were given pefloxacin therapeutically after failure of the initial treatment regimen.
Three doses of pefloxacin were administered at 12-h intervals as a 1-h intravenous (i.v.) infusion in 11 patients and as an oral dose in 4 patients. Individual doses were 7.5 mg/kg in seven patients and 15 mg/kg in eight patients. Pefloxacin was given to all patients during the acute stage of meningitis. After 10 to 14 days of treatment with the other antibiotics, when the meninges were healed, seven patients received three additional doses of pefloxacin.
Concentrations of pefloxacin in CSF were determined 2 h after the end of the infusion and 4 h after oral intake. Blood for plasma assays was obtained just before infusion (trough level) and either at the end of the infusion or 2 h after oral administration (peak level) after the third pefloxacin dose. In patients 14 and 15, a second determination was performed during the period when pefloxacin was used therapeutically in combination with intrathecal administration of gentamicin. No patient had renal or hepatic dysfunction. Informed consent was obtained from each patient or from the family of the patient. All patients were monitored daily for possible adverse reactions, including phlebitis at the injection site, skin rashes, neurological toxicity, diarrhea, and vomiting. Blood sugar, urea nitrogen, hematocrit, leukocyte, and platelet counts and transaminase and alkaline phosphatase activities were measured the day after the last dose was administered.
Assay. The concentrations of pefloxacin in plasma and CSF were determined by high-pressure liquid chromatography. Blood samples were collected in 10-ml heparinized glass test tubes (Vacutainer; Becton, Dickinson & Co., Grenoble, France) and immediately centrifuged for 15 min at 1,200 x g. The plasma fraction was separated and stored at -20°C until assayed. CSF was immediately stored at -20°C.
For high-pressure liquid chromatographic analysis, 1-ml samples of plasma or CSF were mixed with 1 ml of 0.05 M dihydrogen phosphate buffer (pH 2.80) in a 15-ml conical tube and shaken with 10 ml of chloroform for 10 min. The upper aqueous phase was discarded, and the organic phase was washed with 1 ml of buffer (pH 7.1). The aqueous phase was again discarded, and the chloroform phase was evaporated to dryness at 80°C. For plasma samples, the residue was dissolved in 300 ,u of the eluant phase of the chromatographic procedure, and 15 ,u was injected into the chromato- There was no interference with the pefloxacin assay when samples of plasma cQntaining ampicillin (5 and 10 jig/ml), cefotaxime (60 jig/ml), gentamicin (5 and 10 ,ug/ml), and vancomycin (5 and 40 ,ug/ml) were extracted and 15 p1 was injected into the chromatographic column. RESULTS The mean peak levels in plasma of patients receiving 7.5 mg of pefloxacin per kg i.v. twice daily were 10.28 + 1.22 (standard error of the mean [SEM]) p.g/ml, whereas the mean trough levels were 3.54 ± 0.56 (SEM) ,ug/ml. The mean concentrations in CSF were 4.8 ± 0.79 (SEM) ,ug/ml. In patients receiving 15 mg of pefloxacin per kg by the same route, the mean peak levels in plasma were 20.15 ± 1.26 (SEM) jig/ml, and the trough levels were 8.21 ± 1.46 (SEM)
,ug/ml. Mean concentrations in CSF were 8.3 ± 0.98 (SEM) jig/ml. In patients receiving the two doses i.v., the ratio for pefloxacin in CSF to that in plasma was 58% in the group receiving the low dose and 52% in the group receiving the high dose. When the drug was administered orally, the peak levels in plasma for the low dose were 8.2 and 10 ,ug/ml.
Trough levels for the low dose were 6.8 and 3.5 ,ug/ml. Levels in CSF were 3.8 and 3 ,ug/ml after administration of 7.5 mg of drug per kg. In patients who were given 15 mg/kg orally, the concentrations were 21.24 ± 2.24 (SEM) j.g/ml in plasma at the peak and 10.17 + 0.85 (SEM) jxg/ml in CSF. In the seven patients in whom the CSF'concentrations were reassessed after cure of the meningitis, the levels of pefloxacin ranged from 2.7 to 6.4 ,ug/ml in the group receiving the low dose and from 6 to 7.5 jg/ml in the group receiving the high dose. No adverse reactions to pefloxacin were observed during the study. Nevertheless, it must be mentioned that clinical testing of the new quinolones in children is not being done because the drugs cause arthropathy in puppies.
DISCUSSION
In recent studies, it has been shown that some of the new quinolones, including pefloxacin, have a broad spectrum of activity, especially against members of the family Enterobacteriacae, staphylococci, and even Pseudomonas aeruginosa and Acinetobacter sp. (1-3; Duval et al., 13th ICC,  1983) . Therefore, these drugs might be useful in the treatment of systemic infections due to these organisms. In this study, the concentrations of pefloxacin in CSF were equal to or higher than the reported MICs or MBCs against most strains of gram-negative bacilli and staphylococci. Armengaud has found that pefloxacin readily diffuses into the CSF of both normal dogs and those with experimentally induced Staphylococcus aureus meningitis (Armengaud et al., 13th ICC, 1983) . The concentrations in the CSF were 76% of that in serum in dogs with meningitis, as compared with 44.6% in uninfected healthy dogs.
From these preliminary data we suggest that (i) pefloxacin has a good diffusion in inflamed CSF in patients with bacterial meningitis, (ii) the good penetration appears to persist beyond the point at which the meningitis is cured, (iii) CSF concentrations exceed the MICs for most strains (except streptococci), especially when a high dosage is used, (iv) pefloxacin may be useful for the treatment of gramnegative bacilli and staphylococci meningitis or ventriculitis, and (v) further studies are needed to e'valuate CSF bactericidal titers in patients treated with this agent.
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